Apr 27, 2021

Clinical Trial Target & Timeline for Aging Diseases | Ms. Anja Krammer

Posted by in categories: biotech/medical, business, genetics, life extension

CEO of Turn. Bio at 3:40 talking about getting product to market in a few years rather than a decade.

#ERA #sebastiano #turnbio #krammer #stanford #healthspan #aging #longevity.
Ms. Anja Krammer, CEO of Turn Biotechnologies talks about the initial targets for ERA, the time line for clinical trials and FDA approval.
Turn Bio was co-founded by Dr. Vittorio Sebastiano to develop and market the Epigenetic Reprogramming of Aging technology that came out of his lab in Stanford University.
Ms. Krammer is a veteran of F500 healthcare and technology companies and co-founder of three Silicon Valley start ups. She is an entrepreneur who has built biotech, pharmaceutical and consumer businesses by assembling high-performance, results-driven teams and a counsellor to multiple enterprises, who has served on boards of public and private companies, industry organizations and foundation.

Turn Biotechnologies, Inc.

Paper on ERA Technology.
More papers by Dr. Sebastiano.

Comments are closed.